[144] Axalta Coating Systems Ltd. SEC Filing

Rhea-AI Filing Summary

Axalta Coating Systems Ltd. (AXTA) filing a Form 144 notifies a proposed sale of 3,194 shares of common stock through UBS Financial Services on the NYSE with an aggregate market value of $99,208.83. The filing states the shares were acquired via RSU vesting: 1,217 shares vested on 08/23/2024 and 1,977 shares vested on 09/19/2024. The filing reports 216,574,150 shares outstanding and lists the approximate sale date as 08/19/2025. The filer certifies they are not aware of undisclosed material adverse information and provides the standard Rule 144 attestation.

Insights

Securities Analyst

TL;DR: Small director/officer sale notice for 3,194 RSU shares, limited apparent market impact.

The Form 144 documents a proposed sale of 3,194 shares valued at $99,209, executed through UBS on the NYSE with an anticipated trade date of 08/19/2025. The underlying shares arose from RSU vesting in August and September 2024. Relative to the 216.6 million shares outstanding, the volume is immaterial and unlikely to move market prices. The filing includes the standard attestation that no undisclosed material adverse information is known by the seller. From a compliance perspective, the notice satisfies Rule 144 disclosure requirements for an insider sale.

Corporate Governance Expert

TL;DR: Routine insider sale filing; disclosure and timing consistent with RSU vesting and Rule 144 protocols.

The notice indicates the shares to be sold were received via RSU vesting and names the broker and planned sale date. There is no reported prior sale in the past three months. The attestation about lack of material undisclosed information and the explicit listing of acquisition dates align with standard governance and insider-trading controls. Given the small size versus outstanding shares, this filing presents no obvious governance red flags.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	3194	99208.83	216574150	08/19/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/23/2024	RSU Vesting	Axalta Coating Systems Ltd.			1217	08/19/2025	N/A
Common	09/19/2024	RSU Vesting	Axalta Coating Systems Ltd.			1977	08/19/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Axalta's (AXTA) Form 144 disclose about the proposed sale?

The Form 144 discloses a proposed sale of 3,194 common shares through UBS on the NYSE with aggregate value $99,208.83 and an approximate sale date of 08/19/2025.

How were the shares being sold acquired according to the filing?

The filing states the shares were acquired via RSU vesting: 1,217 shares vested on 08/23/2024 and 1,977 shares vested on 09/19/2024.

How many Axalta shares are outstanding per the Form 144?

The filing reports 216,574,150 shares outstanding.

Does the Form 144 indicate any recent sales by the same person in the past three months?

The filing reports "Nothing to Report" for securities sold by the person during the past three months.

What attestation does the seller make in the Form 144?

The seller represents by signing that they do not know of any material adverse information about the issuer that has not been publicly disclosed and references Rule 10b5-1 trading plan language if applicable.